S-edelfosine (S-CP201) / RDP Pharma - LARVOL DELTA

Efficacy and tolerability of a enantiomer of Edelfosine (S-CP201) in pancreatic cancer PDX models as a single agent and in combination with approved drugs in clinical use (AACR 2025) - "Treatment groups included S-CP201, R-CP201 (20 mg/kg p.o. each; given for 5 days/week over 3 w.), Gemcitabine (Gem.; ) (50 mg/kg i.p., 3 d./w. and/or albumin-bound Paclitaxel in pancreatic adenocarcinoma, including in patients with tumors containing mutated Ras. An IND enabling data package is underway."

Clinical • Combination therapy • Genito-urinary Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Prostate Cancer • Solid Tumor • FAS

Non-clinical toxicity studies of S-CP201 (AACR 2025) - "An in vitro hemolysis test (up to 20 µM) was negative for S-CP201. Overall, this S-CP201 non-clinical safety package supports proceeding to Phase 1 studies."

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FAS

Improved pharmacokinetic properties of the purified S-enantiomer of the alkylphospholipid Edelfosine compared to the racemic mixture: Potential orally available novel anticancer agent active against pancreatic cancer (AACR 2025) - "No major toxicity was detected for S-CP201 in rats and mice. These results confirm PK and PD advantages and acceptable tolerability of S-CP201 and support its further development as an anticancer agent is warranted."

PK/PD data • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor • FAS